IntraLase Receives Approval in Taiwan for Sales of Its FS Laser System; Company Plans Immediate Commercialization to Further Expand Global Presence.

IRVINE, Calif. -- IntraLase Corp. (NASDAQ:ILSE), manufacturer of the ultra-fast laser that is revolutionizing refractive and corneal surgery, today announced that Taiwan has granted approval for the sale of the company's femtosecond laser in that nation.

The company plans to immediately commercialize the IntraLase(R) FS laser in Taiwan, further expanding its global presence. As of June 30, 2006, 471 IntraLase lasers were installed around the world and over 850,000 IntraLase LASIK procedures had been performed in ophthalmic practices worldwide.

Taiwan Hwa-In, IntraLase's distributor in Hong Kong and Mainland China, will begin offering the company's products in Taiwan immediately. Mr. Jay Hsu, Chief Executive Officer of Taiwan Hwa-In, stated, "The added safety of the IntraLase Method(TM) in LASIK will provide excellent momentum to drive patient demand in Taiwan, which has a very large number of patients seeking safer and more reliable treatments." Mr. Hsu continued, "Taiwan Hwa-In is a leader in the Taiwanese refractive market, with over 20 years experience, and this approval allows us to help doctors in Taiwan provide bladeless LASIK surgery to their patients."

"The Taiwanese market represents an exciting opportunity and further demonstrates the global potential of IntraLase technology," said Robert J. Palmisano, President and Chief Executive Officer of IntraLase Corp. "We look forward to entering this market and helping Taiwanese practitioners offer clinically-proven safety and improved visual outcomes to their patients."

About IntraLase Corp.

IntraLase designs, develops, and manufactures an ultra-fast laser that is revolutionizing refractive and corneal surgery by creating safe and more precise corneal incisions. Delivering on the promise of ophthalmic laser technology, the IntraLase FS laser, related software, and disposable devices replace the hand-held microkeratome blade used during LASIK surgery. The unsurpassed accuracy of IntraLase's computer-controlled femtosecond laser has been shown to improve safety profiles and visual outcomes when used during LASIK. Additionally, the IntraLase FS laser creates precision-designed intracorneal incisions that when combined can be used during lamellar and penetrating keratoplasty, and intrastromal ring implantation. IntraLase is presently in the process of commercializing applications of its technology in the treatment of corneal diseases that require corneal transplant surgery. The company's proprietary laser and disposable patient interfaces are presently marketed throughout the United States and 31 other countries. IntraLase is headquartered and manufactures its products in Irvine, California. For additional information, visit the company's web site: www.intralase.com.

Forward Looking Statements

Statements contained in this press release that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "project," or words of similar meaning, or future or conditional verbs such as "will," "would," "should," "could," or "may." Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Those risks and uncertainties include, but are not limited to: the degree of continued acceptance of LASIK surgery; potential complications revealed by long-term follow up; the extent of adoption of our product offering by LASIK surgeons; general economic conditions; changes in federal tax laws governing the ability of potential LASIK patients to use pre-tax dollars to pay for LASIK surgery; the scope of government regulation applicable to our products; patients' willingness to pay for LASIK surgery; our ability to compete against our competitors; the effectiveness of our measures to ensure full payment of procedure fees; the occurrence and outcome of product liability suits against us; our ability to adequately protect our intellectual property; whether we become subject to claims of infringement or misappropriation of the intellectual property rights of others; the continued availability of supplies from single-source suppliers and manufacturers of our key laser components; the ability of our managers, operations, and facilities to manage our growth; the success of our expansion into markets outside the United States; whether we lose any of our key executives or fail to attract qualified personnel; or if our new products or applications fail to become commercially viable.

Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's quarterly report on Form 10-Q for the period ending June 30, 2006, as filed with the Securities and Exchange Commission on August 1, 2006.

These forward-looking statements are made only as of the date of this press release, and the company assumes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.